FindTrial
Sign In

Levocarnitine ameliorates acute myocardial injury in children with Kawasaki disease

Levocarnitine ameliorates acute myocardial injury in children with Kawasaki disease by enhancing CPT I activity mediated by oxidative stress

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054514
Enrollment
Unknown
Registered
2021-12-19
Start date
2017-07-01
Completion date
Unknown
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

Experimental group:L-carnitine injection 100mg/kg/d, intravenous drip
Control Group:No

Sponsors

Faculty of Medicine, Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 6 Years

Inclusion criteria

Inclusion criteria: 1. Children with Kawasaki disease who meet the new version of "Typical KD Diagnostic Criteria"; 2. Aged <= 6 years; 3. No previous IVIG or aspirin treatment.

Exclusion criteria

Exclusion criteria: Combined with serious complications, such as heart failure, myocardial infarction, macrophage activation syndrome (MAS), severe gastrointestinal complications, etc.

Design outcomes

Primary

MeasureTime frame
N-terminal pro-B-type natriuretic peptide ;C-reactive protein;white blood cell;left ventricle ejection fraction;left main coronary artery Z value;right coronary artery Z value;reactive oxygen species;nitric oxide;carnitine concentration;—

Countries

China

Contacts

Public ContactZhao Wenwen

Faculty of Medicine, Qingdao University

1320082754@qq.com+86 18006480228

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026